These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8148460)

  • 1. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome.
    Strayer DR; Carter WA; Brodsky I; Cheney P; Peterson D; Salvato P; Thompson C; Loveless M; Shapiro DE; Elsasser W
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S88-95. PubMed ID: 8148460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Adelson ME; Peterson DL; Cheney P; Salvato P; Thompson C; Loveless M; Müller WE
    In Vivo; 1994; 8(4):599-604. PubMed ID: 7893988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
    Strayer DR; Carter WA; Stouch BC; Stevens SR; Bateman L; Cimoch PJ; Lapp CW; Peterson DL; ; Mitchell WM
    PLoS One; 2012; 7(3):e31334. PubMed ID: 22431963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements.
    Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR
    In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome.
    Suhadolnik RJ; Reichenbach NL; Hitzges P; Sobol RW; Peterson DL; Henry B; Ablashi DV; Müller WE; Schröder HC; Carter WA
    Clin Infect Dis; 1994 Jan; 18 Suppl 1():S96-104. PubMed ID: 8148461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
    Mitchell WM
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):755-70. PubMed ID: 27045557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA drug therapy acting via the 2-5A synthetase/RNase L pathway.
    Suhadolnik RJ; Reichenbach NL; Hitzges PM; Ablashi DV; Strayer DR; Carter WA
    Ann N Y Acad Sci; 1993 Jun; 685():756-7. PubMed ID: 8363281
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
    Strayer DR; Young D; Mitchell WM
    PLoS One; 2020; 15(10):e0240403. PubMed ID: 33119613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers.
    Hendrix CW; Margolick JB; Petty BG; Markham RB; Nerhood L; Farzadegan H; Ts'o PO; Lietman PS
    Antimicrob Agents Chemother; 1993 Mar; 37(3):429-35. PubMed ID: 7681656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.
    Smith ME; Haney E; McDonagh M; Pappas M; Daeges M; Wasson N; Fu R; Nelson HD
    Ann Intern Med; 2015 Jun; 162(12):841-50. PubMed ID: 26075755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment proposed for chronic fatigue syndrome; research continues to compile data on disorder.
    Cotton P
    JAMA; 1991 Nov; 266(19):2667-8. PubMed ID: 1942408
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatigue that doesn't go away.
    Propsner NM
    N J Med; 1999 Jun; 96(6):29-31. PubMed ID: 10384764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial.
    Roerink ME; Knoop H; Bredie SJ; Heijnen M; Joosten LA; Netea MG; Dinarello CA; van der Meer JW
    Trials; 2015 Oct; 16():439. PubMed ID: 26438161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An hypothesis concerning optimal therapy in HIV disease.
    Gillespie D; Carter WA
    Med Hypotheses; 1992 Jan; 37(1):1-5. PubMed ID: 1569900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of ampligen in human immunodeficiency virus-infected subjects.
    Armstrong JA; McMahon D; Huang XL; Pazin GJ; Gupta P; Rinaldo CR; Schoenfeld DA; Gaccione P; Tripoli CA; Bensasi S
    J Infect Dis; 1992 Oct; 166(4):717-22. PubMed ID: 1527407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR3 agonists as immunotherapeutic agents.
    Nicodemus CF; Berek JS
    Immunotherapy; 2010 Mar; 2(2):137-40. PubMed ID: 20635920
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific RNA drug therapy of hepatitis viruses.
    Carter WA; Suhadolnik RJ; Müller WE; Korba BE; Hubbell HR; Garcia G; Strayer DR
    Ann N Y Acad Sci; 1993 Jun; 685(1):758-61. PubMed ID: 8363282
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
    Montoya JG; Kogelnik AM; Bhangoo M; Lunn MR; Flamand L; Merrihew LE; Watt T; Kubo JT; Paik J; Desai M
    J Med Virol; 2013 Dec; 85(12):2101-9. PubMed ID: 23959519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease.
    Carter WA; Ventura D; Shapiro DE; Strayer DR; Gillespie DH; Hubbell HR
    Int J Immunopharmacol; 1991; 13 Suppl 1():69-76. PubMed ID: 1688087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.